Action ANTHERA PHARMACEUTICALS INC
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues Anthera Pharmaceuticals Inc Nasdaq

Actions

US03674U3005

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from S&P TMI Index
Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from NASDAQ Composite Index
Anthera Pharmaceuticals, Inc. Reports Top Line Data from the Result Phase 3 Clinical Study of Sollpura
Anthera Mulls Acquisitions
Anthera Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017
Anthera Pharmaceuticals, Inc. Concludes Last Patient Visit in the Phase 3 Result Clinical Study of Sollpura
Anthera Pharmaceuticals, Inc. announced that it has received $15 million in funding from a group of investors
Anthera Pharmaceuticals, Inc. Appoints Patrick Murphy as Senior Vice President, Manufacturing
Anthera Pharmaceuticals, Inc. Announces Positive Outcome of Interim Futility Analysis in the Phase 3 Result Clinical Study of Sollpura
Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura
Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017
Anthera Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from a group of investors
Anthera Pharmaceuticals, Inc. Announces Top Line Final Data from Phase 2 BRIGHT-SC Study of Blisibimod
Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017
Anthera Pharmaceuticals, Inc. Announces Executive Changes
Anthera Pharmaceuticals, Inc. Announces Commencement of Screening in European Sites in Phase 3 Result Clinical Study of Sollpura
Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) dropped from Russell 3000 Index
Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) dropped from Russell 2000 Index
Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from Russell 2000 Dynamic Index
Anthera Pharmaceuticals Announces Resignation of Klara Dickinson-Eason as Senior Vice President, Chief Regulatory Officer, Effective June 20, 2017
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ANTH
  4. Action
  5. Actualités Anthera Pharmaceuticals Inc
  6. Autres langues